Celerion
and
Ricerca Biosciences
announced the formation of “The Biosimilars Alliance”. The Biosimilars Alliance is focused on preclinical and early clinical assessment of biologics manufactured by a new supplier.
The formation of The Biosimilars Alliance was driven by client demand for an integrated service solution for the development of biosimilar products. The market for biosimilars is forecast to grow from $2.4B in 2012 to $44B by 2020. While there has been an established pathway for the approval of biosimilar products in Europe for several years, the US FDA has only recently issued its guidances. The foundation now exists for development of newly sourced versions of some of the most effective treatments that have emerged from medical research in the last 20 years.
The Biosimilars Alliance offers convenient access to all of the specialized services required to perform early assessment of the viability of a potential biosimilar product before beginning costly multi-center comparator studies in the target patient populations. These services include in vitro and in vivo pharmacological assessments of activity and toxicological and immunotoxicological studies to support CTAs and INDs. Importantly, the Biosimilars Alliance also provides access to bioanalytical assay development to enable pharmacokinetic (PK) and pharmacodynamic (PD) assessments in animal and human studies, PK/PD modeling, immunogenicity screening during clinical studies, and the regulatory and integrated project management support to ensure timely results for strategic decision-making.
“The announcement of The Biosimilars Alliance demonstrates Celerion’s ability to respond to client needs and offer effective solutions that leverage the knowledge base built up over the past 20 years of supporting biologic drug development,” said Susan Thornton PhD, President and CEO at Celerion. “The formation of The Biosimilars Alliance is consistent with Celerion’s goal of providing fully integrated services to get to go/no go decisions quickly.”
“Ricerca Biosciences is well positioned in Europe, Asia and North America to enhance the success of The Biosimilars Alliance. Biosimilars are a rapidly growing segment of the market and we see increasing demand from our clients for safety and efficacy testing to assess viability,” said Ian Lennox, CEO of Ricerca. “The Biosimilars Alliance is an important step for Ricerca in supporting the future needs of our clients.”
The Biosimilars Alliance will also work with other solution providers to offer the full scope of services required to bring biosimilar products to market.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.